The relationship between preliminary efficacy and prognosis after first-line EGFR tyrosine kinase inhibitor (EGFR-TKI) treatment of advanced non-small cell lung cancer

DOI: 10.21037/atm.2019.04.06

Keywords: Non-small cell lung cancer (NSCLC), EGFR tyrosine kinase inhibitor (EGFR-TKI), first-line treatment, preliminary efficacy, progression-free survival (PFS)

Full-Text   Cite this paper   Add to My Lib

Abstract:

Full-Text